<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathology of malignant pleural mesothelioma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathology of malignant pleural mesothelioma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathology of malignant pleural mesothelioma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Leslie A Litzky, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Nicholson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James R Jett, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rogerio C Lilenbaum, MD, FACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Mesothelioma is a malignant tumor that arises from the mesothelial surfaces of the pleural and peritoneal cavities, the tunica vaginalis, or the pericardium. Eighty percent of all cases are pleural in origin.</p><p>The pathology of malignant mesothelioma, focusing on the most common form, diffuse pleural malignant mesothelioma, will be reviewed here. The pathology of peritoneal mesothelioma is discussed separately, as are other aspects of pleural mesothelioma. (See  <a class="medical medical_review" href="/z/d/html/2504.html" rel="external">"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging", section on 'Histology'</a> and  <a class="medical medical_review" href="/z/d/html/4625.html" rel="external">"Epidemiology of malignant pleural mesothelioma"</a> and  <a class="medical medical_review" href="/z/d/html/4627.html" rel="external">"Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma"</a> and  <a class="medical medical_review" href="/z/d/html/4626.html" rel="external">"Initial management of malignant pleural mesothelioma"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DIAGNOSTIC DIFFICULTIES</span><span class="headingEndMark"> — </span>Multiple factors have made the diagnosis of malignant mesothelioma a particular challenge for most practicing pathologists.</p><p class="bulletIndent1"><span class="glyph">●</span>Malignant mesothelioma is rare, except in large referral centers or epidemiologic hotspots.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In many cases, only cytologic material or a limited amount of tissue is available for pathologic evaluation and special studies. The use of video-assisted thoracoscopy (VAT) biopsies has made this issue less frequent in many practice settings. VAT has greatly improved the size of pleural biopsies and the choice of sampling sites, usually providing enough tissue for definitive diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignant mesothelioma can vary greatly in histologic appearance within any one patient. In addition, a number of other tumors, either originating within the thorax or metastatic from an extrathoracic site, can mimic malignant mesothelioma. There are also a number of benign pleural diseases that may be difficult to separate from pleural malignancy.</p><p></p><p>The widespread availability and use of immunohistochemistry has greatly improved the accuracy of diagnosis. Molecular studies, although not always available, have also improved diagnostic accuracy in certain situations.</p><p>Finally, a thorough clinical history that includes a history of prior malignancy as well as past medical diseases and previous therapies is essential to appropriate pathologic examination. High quality radiographic studies and astute radiographic assessment can also make a substantial contribution to pathologic diagnosis.</p><p class="headingAnchor" id="H3"><span class="h1">GROSS PATHOLOGY</span><span class="headingEndMark"> — </span>Early stage malignant pleural mesothelioma presents as multiple small nodules that characteristically are more pronounced on the parietal pleura but can also involve the visceral pleura [<a href="#rid1">1</a>]. As the tumor progresses, these nodules coalesce to form a thickened rind of tumor that fuses the parietal and visceral pleurae.</p><p>At a more advanced stage, the tumor typically encases the entire lung and extends along the interlobar fissures (<a class="graphic graphic_picture graphicRef62406" href="/z/d/graphic/62406.html" rel="external">picture 1</a>). This thick rind of tumor can reach diameters of several centimeters or more, despite only minimal invasion of the underlying lung parenchyma. The consistency of the tumor varies from firm to gelatinous.</p><p>Adjacent structures can be involved at an early stage, with invasion of the chest wall, pericardium, and diaphragm. Seventy percent of patients will have mediastinal lymph node involvement at autopsy. Hematogenous metastases are more common than many clinicians assume, particularly to liver, lung, bone, and adrenal glands. Rare localized variants of malignant mesothelioma have also been described [<a href="#rid2">2</a>].</p><p>The gross appearance is not pathognomonic for mesothelioma and there are other primary and secondary pleural malignancies that can diffusely involve the pleura.</p><p class="headingAnchor" id="H4"><span class="h1">HISTOLOGY</span><span class="headingEndMark"> — </span>Malignant mesothelioma is typically classified into three broad histologic subtypes - epithelioid, sarcomatoid, and biphasic (mixed) [<a href="#rid1">1</a>]. Although there are a number of unusual and rare variants, this categorization has general diagnostic utility in that the differential diagnosis of both benign and malignant lesions, as well as the subsequent immunohistochemical work-up, is guided by this subclassification.</p><p class="bulletIndent1"><span class="glyph">●</span>The epithelioid variant is the most common, comprising about 60 percent of all mesotheliomas. Typical histologic appearances of this subtype include tubulopapillary, acinar (glandular), adenomatoid and solid epithelioid patterns (<a class="graphic graphic_picture graphicRef75689" href="/z/d/graphic/75689.html" rel="external">picture 2</a>). In addition to reactive mesothelial hyperplasia, the differential diagnosis includes metastatic carcinomas and other epithelioid tumors. Although not yet formally incorporated into the Mesothelioma Consensus Guidelines, a number of published studies have supported the utility of a nuclear grading system specifically for epithelioid mesothelioma in addition to pleomorphic features [<a href="#rid3">3</a>]. The grading system is based on a score for nuclear atypia and mitotic count, as well as the presence or absence of necrosis. Although grading of epithelioid mesothelioma was not routinely performed in many medical centers prior to the 2021 World Health Organization (WHO) classification, it is now recommended in both biopsy and resection specimens to help in the identification of tumors that may behave in a more aggressive fashion [<a href="#rid1">1</a>]. Pleomorphic features (specifically prominent anaplastic/bizarre nuclei and multinucleated giant cells) can be seen in the epithelioid type and should be noted. Lymphohistiocytoid features (characterized by dense lymphoid infiltrates composed mainly of CD8-positive T-cells that obscure the malignant histiocytoid-appearing tumor cells) similarly should be reported. Both pleomorphic and lymphohistiocytoid features can be seen in biphasic or sarcomatoid subtypes and should be recorded as well.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sarcomatoid mesotheliomas are composed of malignant spindle cells which may mimic malignant mesenchymal tumors, such as leiomyosarcoma or synovial sarcoma. Desmoplastic mesothelioma, which consists of bland tumor cells between dense bands of collagenous stroma, is considered to be a subtype of sarcomatoid mesothelioma. In addition to fibrous pleurisy, the differential diagnosis includes sarcomatoid carcinoma and other sarcomas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biphasic or mixed mesotheliomas have epithelioid and sarcomatoid features, but multiple tissue sections or larger samples may be needed to demonstrate both components. Synovial sarcoma, as well as other mixed or biphasic tumors, are typically considered within this differential diagnosis.</p><p></p><p>Some malignant mesotheliomas are so poorly differentiated and discohesive that lymphomas and non-neoplastic inflammatory disorders must be included within the differential diagnosis [<a href="#rid4">4</a>].</p><p>The entity previously termed as "well-differentiated papillary mesothelioma" has been removed from the mesothelioma WHO classification and is now its own distinct entity. This particular entity has been renamed "well-differentiated papillary mesothelial tumor" and is restricted to a rare and distinctive mesothelial tumor that is composed of papillary stromal formations covered by cytologically bland mesothelial cells lacking invasion [<a href="#rid1">1</a>]. This type of tumor is more commonly diagnosed in the peritoneum. (See  <a class="medical medical_review" href="/z/d/html/2504.html" rel="external">"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging"</a>.)</p><p>Histologic criteria have been described to distinguish reactive mesothelial hyperplasia from epithelioid malignant mesothelioma and fibrous pleurisy from the desmoplastic variant of sarcomatoid mesothelioma [<a href="#rid5">5,6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Reactive mesothelial hyperplasia can be caused by infections, connective tissue disease, pulmonary infarct, drug reactions, pneumothorax, subpleural lung carcinomas, surgery, or traumatic injury.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibrous pleurisy can be the result of asbestos exposure, infection, connective tissue disease, or traumatic injury.</p><p></p><p>The most reliable criterion for distinguishing reactive mesothelial hyperplasia and fibrous pleurisy from malignancy is the demonstration of stromal invasion. Although the recognition of stromal invasion can be highlighted by positive cytokeratin staining, definitive diagnosis is best achieved by adequate biopsies that include some underlying fibroadipose tissue or, in special circumstances, the pulmonary parenchyma.</p><p class="headingAnchor" id="H5"><span class="h2">Immunohistochemistry</span><span class="headingEndMark"> — </span>The use of immunohistochemical panels is an integral part of the diagnosis of malignant mesothelioma.</p><p>There is no single marker that has sufficiently high sensitivity and specificity for malignant mesothelioma, and it is, therefore, standard practice for pathologists to employ a panel of markers (both positive and negative). Institutions vary somewhat in their selection of which markers to include, and panels are typically refined as publications appear with studies comparing the utility of different markers. As a general rule, it is recommended that the marker have either sensitivity or specificity greater than 80 percent for the tumors being considered. When interpreting positivity, both the localization of the stain (nuclear versus cytoplasmic) and the percentage of cells staining positively (&gt;10 percent is suggested for cytoplasmic markers) is recommended [<a href="#rid7">7</a>]. Marker utility is further subdivided into panels which will be more helpful when the tumor appears to be epithelioid, sarcomatoid, or poorly differentiated [<a href="#rid7">7</a>].</p><p>Some general principles can be summarized as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Pancytokeratin stains are very useful in the diagnosis of mesothelioma and will stain the vast majority of mesotheliomas. If the tumor is pancytokeratin negative, then the screening panel should be broadened to include stains to exclude lymphoma, melanoma, angiosarcoma or epithelioid hemangioendothelioma. There are rare sarcomatoid mesotheliomas which are cytokeratin negative, particularly those with osteosarcomatous differentiation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For epithelioid mesothelioma, common positive immunohistochemical markers that can be used to support a diagnosis of malignant mesothelioma include calretinin, CK5/6, the Wilms' tumor-I (WT1) antigen (nuclear staining), and D2-40 (podoplanin) [<a href="#rid1">1</a>]. Useful markers that are positive in pulmonary adenocarcinoma include MOC-31, BG8, carcinoembryonic antigen (monoclonal), B72.3, Ber-EP4, TTF-1, and napsin A (Leu-M1) (<a class="graphic graphic_diagnosticimage graphicRef119314" href="/z/d/graphic/119314.html" rel="external">image 1</a>) [<a href="#rid7">7</a>]. When the differential diagnosis is broadened to include other subtypes of lung tumors such as squamous cell carcinoma or metastases from other primary sites such as the kidney or ovary, then the panel must be more specifically directed toward those considerations and the significance of a positive or negative result must be carefully evaluated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For sarcomatoid or biphasic mesothelioma, cytokeratin reactivity does not necessarily differentiate malignant mesothelioma from other sarcomas, particularly if the cytokeratin staining is focal. Multiple cytokeratin antibodies such as AE1/3 or CAM5.2 should be used since cytokeratin expression can be focal, weak or variable [<a href="#rid8">8</a>]. Significant cytokeratin positivity can also be seen in sarcomatoid carcinoma or metastatic sarcomatoid renal cell carcinoma. D2-40 and calretinin are the most reliable of the affirmative mesothelioma markers [<a href="#rid9">9,10</a>]. D2-40 and calretinin do show overlap reactivity with other types of sarcoma, but a positive result may be useful for confirming a diagnosis of sarcomatoid mesothelioma when combined with strong cytokeratin positivity [<a href="#rid9">9,10</a>]. The possibility of synovial sarcoma can usually be confirmed by molecular testing for the specific X:18 translocation.</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Electron microscopy</span><span class="headingEndMark"> — </span>As the number of antibodies suitable for immunohistochemistry on routine formalin-fixed paraffin embedded tissue has increased and included the addition of affirmative mesothelioma markers, immunohistochemistry has effectively replaced electron microscopy in its traditional use as the "gold standard" for diagnosing malignant mesothelioma.</p><p>Electron microscopy is still occasionally useful in establishing the diagnosis of well to moderately differentiated epithelioid tumors, when the immunohistochemical results are equivocal [<a href="#rid11">11</a>]. The electron microscopic features of malignant mesothelioma have been well characterized [<a href="#rid12">12</a>]. The predominant epithelioid form is composed of polygonal cells with numerous long surface microvilli, prominent desmosomes, and abundant tonofilaments (<a class="graphic graphic_picture graphicRef69168" href="/z/d/graphic/69168.html" rel="external">picture 3</a>).</p><p class="headingAnchor" id="H3699174319"><span class="h2">Molecular markers</span><span class="headingEndMark"> — </span>The use of fluorescent in-situ hybridization (FISH) to detect p16 deletion is now used in challenging cases where the differential diagnosis is benign versus malignant mesothelial proliferations [<a href="#rid7">7</a>]. This type of testing is available at high-volume referral hospitals and through some commercial laboratories. In a similar strategy, detection of loss of breast cancer susceptibility gene 1 (<em>BRCA1</em>)-associated protein (BAP1) by immunohistochemistry can be used to distinguish malignant mesothelioma from reactive mesothelial proliferation [<a href="#rid13">13,14</a>].</p><p class="headingAnchor" id="H7"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Mesothelioma is a malignant tumor that arises from the mesothelial surfaces, most commonly in the pleural cavity, but occasionally in the peritoneal cavity or elsewhere. Malignant mesotheliomas are classified into three major subtypes: epithelioid, sarcomatoid, and biphasic (mixed). (See <a class="local">'Histology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of mesothelioma can be difficult for several reasons. Various metastatic tumors can present in the pleural cavity. Histologically these can look similar to mesotheliomas, as can benign lesions arising in the pleural cavity. (See <a class="local">'Diagnostic difficulties'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunohistochemistry panels are an integral part of the diagnostic approach to these tumors in addition to routine histologic examination. Electron microscopy may be useful when the immunohistochemistry results are equivocal. (See <a class="local">'Immunohistochemistry'</a> above and <a class="local">'Electron microscopy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Borczuk AC, Cooper WA, Dacic S. Tumors of the pleura and pericardium. In: Thoracic Tumours: WHO Classification of Tumours, 5th ed, World Health Organization, 2021. p.500.</li><li><a class="nounderline abstract_t">Allen TC, Cagle PT, Churg AM, et al. Localized malignant mesothelioma. Am J Surg Pathol 2005; 29:866.</a></li><li><a class="nounderline abstract_t">Zhang YZ, Brambilla C, Molyneaux PL, et al. Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2-tier nuclear grade. Histopathology 2020; 77:423.</a></li><li><a class="nounderline abstract_t">Allen TC. Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies. Arch Pathol Lab Med 2005; 129:1415.</a></li><li><a class="nounderline abstract_t">Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000; 24:1183.</a></li><li><a class="nounderline abstract_t">Mangano WE, Cagle PT, Churg A, et al. The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining. Am J Clin Pathol 1998; 110:191.</a></li><li><a class="nounderline abstract_t">Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med 2018; 142:89.</a></li><li><a class="nounderline abstract_t">Mayall FG, Goddard H, Gibbs AR. The diagnostic implications of variable cytokeratin expression in mesotheliomas. J Pathol 1993; 170:165.</a></li><li><a class="nounderline abstract_t">Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005; 18:105.</a></li><li><a class="nounderline abstract_t">Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol 2004; 35:697.</a></li><li><a class="nounderline abstract_t">Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol 2006; 19:417.</a></li><li><a class="nounderline abstract_t">Hammar SP. Macroscopic, histologic, histochemical, immunohistochemical, and ultrastructural features of mesothelioma. Ultrastruct Pathol 2006; 30:3.</a></li><li><a class="nounderline abstract_t">Sheffield BS, Hwang HC, Lee AF, et al. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol 2015; 39:977.</a></li><li><a class="nounderline abstract_t">Scherpereel A, Opitz I, Berghmans T, et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J 2020; 55.</a></li></ol></div><div id="topicVersionRevision">Topic 4608 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Borczuk AC, Cooper WA, Dacic S. Tumors of the pleura and pericardium. In: Thoracic Tumours: WHO Classification of Tumours, 5th ed, World Health Organization, 2021. p.500.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15958850" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Localized malignant mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32333813" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2-tier nuclear grade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16253022" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10976692" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The separation of benign and malignant mesothelial proliferations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704618" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28686500" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7688419" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The diagnostic implications of variable cytokeratin expression in mesotheliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389250" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15188136" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16415794" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16517466" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Macroscopic, histologic, histochemical, immunohistochemical, and ultrastructural features of mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25634745" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32451346" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
